MedTrace Logo

Coenzyme Q10 as Treatment for Long Term COVID-19

NCT04960215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2022-05-06

No results posted yet for this study

Summary

This study is a randomized, placebo-controlled, double-blinded, cross-over designed clinical trial investigating the effect of high-dose Coenzyme Q10 treatment in subjects with persisting symptoms more than 12 weeks af SARS-CoV-2 infection, Long Term COVID-19 (LTC).

Conditions

  • Covid19
  • Long Term Covid19

Interventions

DRUG

Coenzyme Q10

Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.

DRUG

Placebo

A soft gelatin capsule containing soy oil, 5 capsules a day.

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Pharma Nord

    collaborator INDUSTRY

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Line Khalidan Vibholm, M.D., Ph.D · Department of Infections Diseases, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2022-02-10
Completion
2022-02-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04960215 on ClinicalTrials.gov